Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daewoong To Sell Medivir 's Xerclear in Korea As Swedish Firm Looks For More Partners

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Daewoong Pharmaceutical - one of the leading local pharmas - signed an agreement with Medivir to sell the latter's OTC cold sore treatment Xerclear (acyclovir and hydrocortisone) in Korea, as Medivir continues to seek partners for the drug outside of its primary markets

You may also be interested in...



Green Cross And MNC-Linked Daewoong Stand Out In Korea's Sluggish 3rd Quarter

SEOUL - South Korea's top five pharma companies - excluding Green Cross and Daewoong Pharmaceutical - posted sluggish sales in the third quarter, most of them still finding ways to cope with the government's tightening grip on their business practices

Green Cross And MNC-Linked Daewoong Stand Out In Korea's Sluggish 3rd Quarter

SEOUL - South Korea's top five pharma companies - excluding Green Cross and Daewoong Pharmaceutical - posted sluggish sales in the third quarter, most of them still finding ways to cope with the government's tightening grip on their business practices

GSK Expands Consumer Business With Acquisition Of OTC Cold Sore Products

GlaxoSmithKline further expands its rapidly growing consumer health care business by acquiring exclusive marketing rights to two cold sore treatments in a week, just months after announcing a third deal in the category

Latest News
See All
UsernamePublicRestriction

Register

SC075750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel